A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43912199" target="_blank" >RIV/00216208:11120/17:43912199 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/17:N0000024
Result on the web
<a href="http://dx.doi.org/10.1111/ejh.12807" target="_blank" >http://dx.doi.org/10.1111/ejh.12807</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ejh.12807" target="_blank" >10.1111/ejh.12807</a>
Alternative languages
Result language
angličtina
Original language name
A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice
Original language description
OBJECTIVE: Romiplostim has maintained long-term platelet counts in patients with immune thrombocytopenia (ITP) for up to 5 years in clinical studies. This prospective observational study aimed to describe romiplostim utilisation and outcomes in European clinical practice. METHODS: Adults with primary ITP who received romiplostim in routine care were eligible. RESULTS: Three-hundred and forty patients were eligible for analysis, of whom 299 (88%) completed the two-year observation period. The median age was 62 years, with 43% of patients aged GREATER-THAN OR EQUAL TO65 years, and two-thirds of patients initiated romiplostim before splenectomy. The median average weekly dose of romiplostim was 2.8 μg/kg. The median baseline platelet count was 20 x 10(9) /L, which increased after 2 weeks of romiplostim treatment and remained >50 x 10(9) /L thereafter. After romiplostim initiation, there was a decrease in rates of grade GREATER-THAN OR EQUAL TO3 bleeding events (from 12 to 2 per 100 patient-years) and ITP-related hospitalisations (from 87 to 33 per 100 patient-years). The rate of thrombotic events was 2 per 100 patient-years and bone marrow fibrosis occurred in two patients. CONCLUSIONS: Romiplostim dosing, effectiveness, and safety in an unselected real-world ITP population seemed comparable with that observed in clinical studies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Haematology
ISSN
0902-4441
e-ISSN
—
Volume of the periodical
98
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
112-120
UT code for WoS article
000393167400002
EID of the result in the Scopus database
2-s2.0-84994344530